Stock Message Board Recent Posts http://investorshangout.com/search?q=EXEL&...mp;yt0=Go!
Last Updated: 10/09/2015 20:07:06
Current Price and Quotes
Last Price 5.985
Previous Close 5.85 Open 5.84
Daily Range 5.76 - 5.99 52wk Range 1.26 - 6.80
Volume 2,923,251 Dividend N/A
Average Vol (30d) 6,317,029 Net Dividend Yield N/A
Financials
Period Ending Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011
Total Revenue 25,111 31,338 47,450 289,636
Cost of Revenue 2,043 1,118 - -
Gross Profit 23,068 30,220 47,450 289,636
Operating Expenses
Research and Development 189,101 178,763 128,878 156,836
Sales, General and Admin. 50,829 50,958 31,837 33,129
Non-Recurring Items 7,596 1,231 9,171 10,136
Other - - - -
Operating Income (224,458) (200,732) (122,436) 89,535
Income From Continuing Operations
Add'l Income/Expense Items 4,341 1,223 1,986 3,716
Earnings Before Interest and Tax (220,117) (199,509) (120,450) 93,251
Interest Expense 48,607 45,347 27,088 16,259
Earnings Before Tax (268,724) (244,856) (147,538) 76,992
Income Tax (182) (96) 107 1,295
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (268,542) (244,760) (147,645) 75,697
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (268,542) (244,760) (147,645) 75,697
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (268,542) (244,760) (147,645) 75,697
Recent News
Source
Oct 6, 2015 Premarket Gainers / Losers as of 9:10 am Seeking Alpha
Oct 6, 2015 Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma BUSINESS WIRE
Sep 30, 2015 Stock Movement Prior To Phase III Trial Releases: Penny Stocks Rise While Big Stocks Fall Seeking Alpha
Sep 29, 2015 Top 3 Trade Alert Ideas September 25: Exelixis's Cobimetinib, Merck For Dividends, Progenics Catalysts Seeking Alpha
Sep 25, 2015 Exelixis Announces Positive Results from METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Presented at European Cancer Congress 2015 BUSINESS WIRE
Sep 25, 2015 European CHMP Adopts Positive Opinion for Cobimetinib in Combination with Vemurafenib for the Treatment of Advanced Melanoma BUSINESS WIRE
Sep 24, 2015 Technical Coverage on Stocks from Diverse Sectors - CME Group, Commerce Bancshares, Conatus Pharmaceuticals, Exelixis and CTI BioPharma PR NEWSWIRE
Sep 24, 2015 Exelixis Announces Key Senior Leadership Hires in Medical Affairs, Sales, and Marketing to Support Commercialization of Cabozantinib and Cobimetinib BUSINESS WIRE
Sep 22, 2015 Exelixis to Host Investor/Analyst Webcast During European Cancer Congress 2015 BUSINESS WIRE
Sep 21, 2015 Biotechnology Stocks Technical Study -- Exelixis, XOMA Corp., Enzon Pharma, Peregrine Pharma, and StemCells PR NEWSWIRE
1
2
3
4
5
6
7
8
next >
EXEL Exelixis, Inc. Research DD Guide
Stock Message Board http://investorshangout.com/search?q=EXEL&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/EXEL/quote
Stock Chart http://www.otcmarkets.com/stock/EXEL/chart
Company Info http://www.otcmarkets.com/stock/EXEL/company-info
Recent News http://www.otcmarkets.com/stock/EXEL/news
Financials http://www.otcmarkets.com/stock/EXEL/financials
Filings and Disclosure http://www.otcmarkets.com/stock/EXEL/filings
Short Sales http://www.otcmarkets.com/stock/EXEL/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/EXEL/insider-transactions
Research Reports http://www.otcmarkets.com/stock/EXEL/research
Summary http://finance.yahoo.com/q?s=EXEL
Historical Prices http://finance.yahoo.com/q/hp?s=EXEL+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=EXEL
Basic Chart http://finance.yahoo.com/q/bc?s=EXEL+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=EXEL+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=EXEL+Headlines
Press Releases http://finance.yahoo.com/q/p?s=EXEL+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=EXEL+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=EXEL+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=EXEL+Industry
Major Holders http://finance.yahoo.com/q/mh?s=EXEL+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=EXEL+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=EXEL+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=EXEL
Balance Sheet http://finance.yahoo.com/q/bs?s=EXEL
Cash Flow http://finance.yahoo.com/q/cf?s=EXEL+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/EXEL
Market Watch http://www.marketwatch.com/investing/stock/EXEL
Bloomberg http://www.bloomberg.com/quote/EXEL:US
Morningstar http://quotes.morningstar.com/stock/s?t=EXEL
Bussinessweek http://investing.businessweek.com/research/st...icker=EXEL
Barchart http://www.barchart.com/quotes/stocks/EXEL
OTC Short Report http://otcshortreport.com/index.php?index=EXEL
Investopedia http://www.investopedia.com/markets/stocks/EXEL/?wa=0